Timms, Liam
Zhou, Tianyi
Lyu, Yue
Qiao, Ju
Mishra, Vishala
Lahoud, Rita Maria
Jayaraman, Gayatri Veeramani
Allegretti, Andrew S.
Drew, David
Seethamraju, Ravi T.
Harisinghani, Mukesh
Sridhar, Srinivas
Funding for this research was provided by:
National Institute on Drug Abuse (1R41DA043974-01)
National Institute of Diabetes and Digestive and Kidney Diseases (1R21DK118449-01)
Article History
Received: 4 December 2020
Revised: 28 January 2021
Accepted: 9 February 2021
First Online: 5 March 2021
Compliance with ethical standards
:
: RTS reports personal fees from Siemens Medical Solutions, Inc., outside the submitted work. SS reports grants from Theranano LLC and grants from Northeastern University, during the conduct of the study; In addition, SS has a patent WO2017019182A1 pending.
: This study was conducted with approval by the Massachusetts General Hospital Institutional Review board IRB:2017P001262. All procedures performed in the study involving human participants were Heal Insurance Portability and Accountability Act (HIPAA) compliant.
: Subjects provided informed written consent for the imaging procedure which is an off-label use of ferumoxytol.